The FDA is tightening regulations on stem cell therapies and exosome-based products, issuing multiple warning letters for cGMP violations, misbranding, and unapproved biologic manufacturing. Companies affected include Chara Biologics, INCELL Corporation, Neobiosis, and Platinum Biologics.
The enforcement wave raises three questions for the industry:
- Are exosome therapy and stem cell products drugs or tissue allografts?
- Is the FDA moving the goalposts on stem cell approval?
- How will this affect patients, biotech companies, and regulatory pathways?
Why the FDA Is Cracking Down
Drugs or transplants?
The FDA considers perinatal-derived exosome and stem cell products biologic drugs, requiring full clinical trials and approval before marketing. Many biotech firms argue the same products are minimally manipulated tissue products, more analogous to bone marrow transplants.
“cGMP standards are the right way to go for perinatal products for most applications out there being marketed and I see them as drugs. Others see it differently though.”
— Dr. Paul Knoepfler, stem cell biologist at UC Davis
Why approval standards are shifting
- Stem cell therapies were previously categorized under tissue allografts, allowing use under Section 361 without extensive approval.
- Expanded stem cells and allogeneic products now require clinical trials, per new FDA guidance.
- Exosome therapy faces stricter scrutiny — as of 2025, no exosome products are FDA-approved.
The agency now requires clinical trials, cGMP compliance, and full biologics approval for these therapies.
Case Studies: Chara Biologics and INCELL
Two of the most notable warning letters went to Chara Biologics and INCELL Corporation.
Chara Biologics
Cited for marketing umbilical-derived stem cells without FDA approval, failing cGMP compliance for manufacturing standards, and suggesting unproven therapeutic benefits.
INCELL Corporation
Dr. Mary Pat Moyer, CEO of INCELL, disputes the FDA’s stance:
“The Warning Letters to INCELL and XoBiologix are an attack on two small businesses providing clinical products important for helping people. There have been no reported patient safety concerns.”
Moyer argues that INCELL’s amniotic-derived product, MaviX, is a sterile flowable allograft — not a drug. Read more here.
The FDA maintains that any regenerative product used to treat disease must go through the full drug approval process. Classifying perinatal-derived products as biologic drugs rather than tissue allografts is forcing biotech firms to meet new standards.
Is the FDA Stifling Innovation?
Many in the regenerative medicine industry argue the FDA’s evolving stance limits access to potentially life-changing therapies.
Arguments for FDA oversight
- Prevents low-quality or contaminated products from entering the market (more here).
- Ensures scientific validation through clinical trials.
- Protects patients from misleading marketing claims.
Arguments against
- Creates barriers for small biotech firms, favoring larger pharmaceutical companies.
- Shifts regulatory definitions, moving the goalposts for approval.
- Limits patient access to promising treatments before formal approval.
Writing in November 2024 about the incoming Trump administration’s FDA, Paul Knoepfler predicted that Martin Makary — Trump’s nominee to lead the FDA — would most likely take the unproven-clinic problem seriously, similar to Scott Gottlieb during the first Trump administration. His more pointed concern was that the FDA’s biologics branch, CBER, had done more on unproven cell-therapy clinics in 2024 than in any prior year, and that momentum could be lost if RFK Jr. as HHS Secretary pressured the FDA to ease enforcement. Knoepfler framed it as uncertainty rather than a prediction of softening: which way enforcement settles depends on leadership choices that take time to surface.
For the canonical regulatory picture — federal framework, state carve-outs (TX, FL, UT, MS), preemption case law, and where cosmetic exosomes sit in the gray zone — see the regulatory landscape page.
What This Means for Patients and Providers
What’s changing in stem cell approval
- Autologous stem cells (from the patient’s own body) may still be used under lower regulation.
- However, some products and processing — including mFAT — have been recently reclassified and subjected to stricter regulation.
- Allogeneic stem cells (from donors) now require full FDA approval.
- Expanded stem cells face stricter clinical trial requirements.
Why no exosome therapy is FDA-approved
- No exosome therapy products are FDA-approved as of 2025.
- Many clinics misrepresent exosome quality, inflating particle counts without verifying therapeutic function.
- The FDA is actively shutting down noncompliant exosome manufacturers.
Patients should verify that providers follow FDA guidelines, use high-quality sources, and operate under proper regulatory oversight.
The Future
The FDA’s crackdown reflects a changing regulatory landscape:
- Exosome therapy and stem cell products are increasingly regulated like biologic drugs, not tissue transplants.
- Companies must decide whether to pursue full FDA approval or operate in the regulatory gray zone.
- Patients should ensure treatments are safe, compliant, and backed by science.